Breast cancer vaccine shows promise in small clinical trial

December 1, 2014 A breast cancer vaccine developed at Washington University School of Medicine in St. Louis is safe in patients with metastatic breast cancer, results of an early clinical trial indicate. Preliminary evidence also suggests that the vaccine primed the patients’ immune systems to attack tumor cells and helped slow the cancer’s progression. The study appears Dec. 1 in Clinical Cancer …

VGTI Florida to Collaborate with TapImmune to Advance Targeted Breast and Ovarian Cancer Vaccines into Phase II Clinical Trials

VGTI Florida to coordinate cancer study design and trial sites selection November 18, 2014 The Vaccine & Gene Therapy Institute of Florida (VGTI Florida), a leading, non-profit biomedical research institute, today announced a new collaborative research agreement with TapImmune, Inc., forming a partnership to advance TapImmune’s proprietary, targeted cancer vaccines into mid-stage, Phase II human clinical trials for the treatment …

Novel immunotherapy vaccine decreases recurrence in HER2 positive breast cancer patients

September 9, 2014 A new breast cancer vaccine candidate, (GP2), provides further evidence of the potential of immunotherapy in preventing disease recurrence. This is especially the case for high-risk patients when it is combined with a powerful immunotherapy drug. These findings are being presented by The University of Texas MD Anderson Cancer Center at the 2014 American Society of Clinical Oncology’s Breast Cancer …

Regen BioPharma Has Reported Progress in Development of dCellVax: A Therapeutic Cancer Vaccine

Regen BioPharma Advances Towards Breast Cancer Immunotherapy

Regen BioPharma Has Reported Progress in Development of dCellVax: A Therapeutic Cancer Vaccine On the 1st of August 2014, Regen BioPharma reported on progress on its therapeutic cancer vaccine dCellVax, which stimulates the immune system of patients to selectively kill tumors. Thomas Ichim, the Chief Scientific Office of Regen BioPharma, said in a statement that ‘we are please to announce …